Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Ionis Pharmaceuticals Inc (IONS)  
$40.00 0.36 (0.91%) as of 4:30 Wed 6/25


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 173,853,000
Market Cap: 6.95(B)
Last Volume: 998,037 Avg Vol: 989,971
52 Week Range: $25.51 - $51.86
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    : 9.8
Insider 6 Months    : 9.8
Insider 3/6 Months : 19.9
Guru Rank Number :  162
Guru Rank Value     : 8.6
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Ionis Pharmaceuticals is engaged in RNA-targeted therapeuty. Co.'s commercial products are SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA injection for intrathecal use is a survival motor neuron-2 directed antisense medicine indicated for the treatment of spinal muscular atrophy in pediatric and adult patients. TEGSEDI injection is an RNA-targeted medicine indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 15,000 15,000 20,000 20,000
Total Buy Value $477,900 $477,900 $658,979 $658,979
Total People Bought 1 1 1 1
Total Buy Transactions 1 1 2 2
Total Shares Sold 7,624 167,029 205,132 760,192
Total Sell Value $216,381 $5,379,126 $7,019,973 $34,452,702
Total People Sold 3 11 14 17
Total Sell Transactions 3 26 35 94
End Date 2025-03-27 2024-12-24 2024-06-25 2023-06-26

   
Records found: 1047
  Page 1 of 42  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Hayden Michael R Director   –       •      –    2025-05-01 4 B $31.86 $477,900 D/D 15,000 50,219 2.39 25%     
   Jenne Kyle EVP, Chf GL Pdt Str Ofcr   •       –      –    2025-04-16 4 S $28.36 $85,534 D/D (3,016) 11,199 -40%     
   Birchler Brian EVP, Corp and Development Ops   •       –      –    2025-04-16 4 S $28.37 $19,292 D/D (680) 56,660 -40%     
   Baroldi Joseph EVP, Chief Business Officer   •       –      –    2025-04-16 4 S $28.40 $111,555 D/D (3,928) 31,926 -40%     
   Jenne Kyle EVP, Chf GL Pdt Str Ofcr   •       –      –    2025-04-15 4 OE $0.00 $0 D/D 12,226 14,215     -
   Birchler Brian EVP, Corp and Development Ops   •       –      –    2025-04-15 4 OE $0.00 $0 D/D 1,875 57,340     -
   Baroldi Joseph EVP, Chief Business Officer   •       –      –    2025-04-15 4 OE $0.00 $0 D/D 10,837 35,854     -
   Monia Brett P Chief Executive Officer   •       •      –    2025-03-11 4 AS $32.32 $4,525 D/D (140) 180,980 13%     
   Monia Brett P Chief Executive Officer   •       •      –    2025-02-28 4 A $28.21 $12,328 D/D 437 181,120     -
   Oneil Patrick R. EVP CLO & General Counsel   •       –      –    2025-02-28 4 A $28.21 $15,629 D/D 554 56,799     -
   Geary Richard S EVP, Chief Development Officer   •       –      –    2025-02-28 4 A $28.21 $11,708 D/D 415 99,492     -
   Bennett C Frank EVP, Chief Scientific Officer   •       –      –    2025-02-28 4 A $28.21 $9,028 D/D 320 93,466     -
   Swayze Eric EVP Research   •       –      –    2025-02-28 4 A $28.21 $11,708 D/D 415 48,432     -
   Birchler Brian EVP, Corp and Development Ops   •       –      –    2025-02-28 4 A $28.21 $11,680 D/D 414 55,465     -
   Oneil Patrick R. EVP CLO & General Counsel   •       –      –    2025-02-20 4 AS $32.35 $39,046 D/D (1,207) 56,245 14%     
   Oneil Patrick R. EVP CLO & General Counsel   •       –      –    2025-02-04 4 AS $31.62 $194,939 D/D (6,165) 57,452 12%     
   Monia Brett P Chief Executive Officer   •       •      –    2025-02-04 4 AS $31.65 $1,229,463 D/D (38,843) 180,683 12%     
   Bennett C Frank EVP, Chief Scientific Officer   •       –      –    2025-01-31 4 S $32.46 $43,079 D/D (1,327) 93,146 -13%     
   Schneider Eugene EVP, Chf Clinical Develop Ofcr   •       –      –    2025-01-31 4 S $32.20 $47,780 D/D (1,484) 61,056 -13%     
   Swayze Eric EVP Research   •       –      –    2025-01-31 4 S $32.31 $44,162 D/D (1,367) 48,017 -13%     
   Monia Brett P Chief Executive Officer   •       •      –    2025-01-31 4 S $32.45 $429,655 D/D (13,242) 219,526 -13%     
   Hougen Elizabeth L EVP, Finance & CFO   •       –      –    2025-01-31 4 S $32.44 $49,404 D/D (1,523) 110,500 -13%     
   Geary Richard S EVP, Chief Development Officer   •       –      –    2025-01-31 4 S $32.40 $45,561 D/D (1,406) 99,077 -13%     
   Oneil Patrick R. EVP CLO & General Counsel   •       –      –    2025-01-31 4 S $32.49 $45,685 D/D (1,406) 63,617 -13%     
   Bennett C Frank EVP, Chief Scientific Officer   •       –      –    2025-01-30 4 A $0.00 $0 D/D 3,607 94,473     -
  1047 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 42
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us